Research programme: glucose metabolism disorder therapeutics - Adocia

Drug Profile

Research programme: glucose metabolism disorder therapeutics - Adocia

Alternative Names: BC GlaD; BC GlaLira; BioChaperone glargine dulaglutide; BioChaperone Glargine GLP-1; BioChaperone glargine liraglutide

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 19 Jul 2017 Adocia plans a clinical trial for Diabetes mellitus in 2017
  • 20 Sep 2016 Preclinical trials in Diabetes mellitus in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top